Part 6: Why Biomarkers Matter in the MT1988 Proof-of-Principle Trial
Previously, we introduced our nicotinic drug MT1988’s journey from concept to clinic as our Proof-of-Principle (PoP) trial in clinical high risk (CHR) for psychosis gets underway (NCT07226895). Here, we take a deeper dive into how biomarkers are central to the trial, why they matter, and how Monument’s proprietary digital biomarker is being evaluated as a […]
Part 5: From Lab to Clinic: Preparing MT1988 For Its First Patient Trial
In our last post, we explored the scientific rationale behind MT1988 and how the history of nicotinic receptor research has shaped its design. In this post we shift gears from why MT1988 matters, to how it has progressed from concept to clinical reality as it enters evaluation in a clinical high risk (CHR) for psychosis […]
Part 4: The History and Science Behind MT1988
In our last post, we introduced the team leading the MT1988 proof-of-principle clinical trial – a major collaboration under the AMP® SCZ programme focused on accelerating early intervention in individuals at clinical high risk (CHR) for psychosis. This week, we explore the science behind MT1988 – its mechanism of action as a nicotinic agonist, how […]
Part 3: Meet the Team Advancing Early Intervention in Psychosis
In our last post, we explored how the clinical high risk (CHR) for psychosis stage can reveal the earliest cognitive and neurobiological impairments linked to psychosis risk, offering an important opportunity to evaluate treatments aligned with those mechanisms. This week, we introduce the scientific and clinical leaders who are driving that work forward through our […]
Part 2: Why CHR Matters – Advancing Early Intervention Through Precision Psychiatry
In our last post, we discussed how precision psychiatry is transforming neuroscience drug development by aligning treatments with the biological mechanisms that drive symptoms. This week, we turn our focus to a key population in that paradigm: people at clinical high risk (CHR) for psychosis. Understanding CHR: The Window of Opportunity Psychotic disorders such as […]
Part 1: Changing the Odds with Precision Psychiatry
Over the last decade, the prevalence of psychiatric disorders has increased by roughly 50% and today’s approved medicines only help about half of the patients who take them. The need for better treatment options for disorders such as depression, schizophrenia and ADHD is therefore substantial, yet approximately 95% of neuroscience drug candidates fail in clinical […]
Monument Therapeutics Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia
Manchester, UK, 19 August 2025 Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in development for cognitive impairment associated with schizophrenia, in a proof of principle clinical trial. Schizophrenia is a severe mental health disorder and ranks […]
Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment
Manchester, UK, 23 June 2025 Monument Therapeutics, a precision neuroscience company, today announced positive topline results from its Phase I clinical trial evaluating MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). MT1988 is a fixed-dose combination of two well-established small molecules that act on nicotinic receptors, designed to optimise safety and efficacy. […]
Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
Manchester, UK, 17 April 2025 Monument Therapeutics, a precision neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has been appointed Non Executive Chair of the Board, effective immediately, and Dr Heather Preston has joined the company’s advisory […]
Monument Therapeutics Secures £850k to Advance Breakthrough Schizophrenia Treatment
Manchester, UK, 25 February 2025 Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used to fund its schizophrenia programme and drive the next stage of growth […]
Monument Therapeutics Announces Grant of Chinese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
Manchester, UK, 21 January 2025 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted Chinese patent ZL202080036867.6, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The patent, […]
Monument Therapeutics Announces Grant of Japanese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
Manchester, UK, 14 January 2025 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the Japan Patent Office (“JPO”) has granted Japanese patent 7570345, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The patent, which is expected […]
Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Manchester, UK, 26 November 2024 Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical study of MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). MT1988 is a fixed-dose combination of two well-established small molecules that act on nicotinic receptors, designed to […]
Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Manchester, UK, 19 November 2024 Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), is pleased to announce the addition of three distinguished experts to its Scientific Advisory Board (SAB). Leading the SAB as the new chairperson is Dr Mark Treherne, a research scientist with […]